Diabetic retinopathy: research to clinical practice

BACKGROUND: Diabetic Retinopathy (DR) is a leading cause of visual impairment in the United States. The CDC estimates that the prevalence of DR will triple from 2005 to 2050. MAIN BODY: The report summarizes major past advances in diabetes research and their impact on clinical practice. Current para...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Anjali R., Gardner, Thomas W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648499/
https://www.ncbi.nlm.nih.gov/pubmed/29075511
http://dx.doi.org/10.1186/s40842-017-0047-y
_version_ 1783272408130519040
author Shah, Anjali R.
Gardner, Thomas W.
author_facet Shah, Anjali R.
Gardner, Thomas W.
author_sort Shah, Anjali R.
collection PubMed
description BACKGROUND: Diabetic Retinopathy (DR) is a leading cause of visual impairment in the United States. The CDC estimates that the prevalence of DR will triple from 2005 to 2050. MAIN BODY: The report summarizes major past advances in diabetes research and their impact on clinical practice. Current paradigms and future directions are also discussed. CONCLUSIONS: DR is a leading cause of visual impairment in the US. Significant progress has been made in the understanding and treatment of DR, but rising prevalence demands innovative approaches to management in the future.
format Online
Article
Text
id pubmed-5648499
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56484992017-10-26 Diabetic retinopathy: research to clinical practice Shah, Anjali R. Gardner, Thomas W. Clin Diabetes Endocrinol Review Article BACKGROUND: Diabetic Retinopathy (DR) is a leading cause of visual impairment in the United States. The CDC estimates that the prevalence of DR will triple from 2005 to 2050. MAIN BODY: The report summarizes major past advances in diabetes research and their impact on clinical practice. Current paradigms and future directions are also discussed. CONCLUSIONS: DR is a leading cause of visual impairment in the US. Significant progress has been made in the understanding and treatment of DR, but rising prevalence demands innovative approaches to management in the future. BioMed Central 2017-10-19 /pmc/articles/PMC5648499/ /pubmed/29075511 http://dx.doi.org/10.1186/s40842-017-0047-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review Article
Shah, Anjali R.
Gardner, Thomas W.
Diabetic retinopathy: research to clinical practice
title Diabetic retinopathy: research to clinical practice
title_full Diabetic retinopathy: research to clinical practice
title_fullStr Diabetic retinopathy: research to clinical practice
title_full_unstemmed Diabetic retinopathy: research to clinical practice
title_short Diabetic retinopathy: research to clinical practice
title_sort diabetic retinopathy: research to clinical practice
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648499/
https://www.ncbi.nlm.nih.gov/pubmed/29075511
http://dx.doi.org/10.1186/s40842-017-0047-y
work_keys_str_mv AT shahanjalir diabeticretinopathyresearchtoclinicalpractice
AT gardnerthomasw diabeticretinopathyresearchtoclinicalpractice

Ejemplares similares